Singapore, Singapore

Lai San Tham

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Eli Lilly and Company. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lai San Tham. Retrieved from https://idiyas.com/inventor/lai-san-tham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Lai San Tham

Introduction

Lai San Tham is a notable inventor based in Singapore, recognized for his contributions to the field of pharmaceuticals. He has made significant strides in developing methods and compositions that enhance the efficacy of medications.

Latest Patents

One of his key patents is titled "Methods of using and compositions containing dulaglutide." This invention focuses on new dosing methods for dulaglutide, a medication used in the treatment of diabetes, and includes compositions that utilize higher doses of this compound.

Career Highlights

Lai San Tham is currently employed at Eli Lilly and Company, a global leader in the pharmaceutical industry. His work at Eli Lilly has allowed him to contribute to innovative solutions that address critical health issues.

Collaborations

He has collaborated with esteemed colleagues, including David Andrew Cox and Zvonko Milicevic, to further advance research and development in his field.

Conclusion

Lai San Tham's innovative work in the pharmaceutical sector, particularly with dulaglutide, showcases his commitment to improving healthcare solutions. His contributions are vital in the ongoing quest for effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…